Asset
RELUSCOVTOGENE RALAPLASMID
Inovio Pharmaceuticals Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04642638 | phase2_3 | terminated | 2020-11-30 | 2022-09-13 | Inovio Pharmaceuticals | Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure |
| NCT04336410 | phase1 | completed | 2020-04-03 | 2022-02-10 | Inovio Pharmaceuticals | Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers |
| NCT05430958 | phase1 | withdrawn | 2022-10-01 | 2024-03-01 | Inovio Pharmaceuticals | Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers |
FDA applications (0)
This company has no applications containing this asset.